Terms: = Brain cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Clinical Outcome
4 results:
1. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the iris study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
2. outcome of triple negative breast cancer: comparison of sporadic and brca1-associated cancers.
Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of triple negative breast cancer in brca1 mutation carriers and noncarriers.
Lee LJ; Alexander B; Schnitt SJ; Comander A; Gallagher B; Garber JE; Tung N
Cancer; 2011 Jul; 117(14):3093-100. PubMed ID: 21264845
[TBL] [Abstract] [Full Text] [Related]
4. Differential diagnosis of anterior chamber cysts with ultrasound biomicroscopy: ciliary body medulloepithelioma.
Zhou M; Xu G; Bojanowski CM; Song Y; Chen R; Sun X; Wang W; Chan CC
Acta Ophthalmol Scand; 2006 Feb; 84(1):137-9. PubMed ID: 16445454
[TBL] [Abstract] [Full Text] [Related]
